A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
Robert F. Kennedy Jr., President-elect Donald Trump’s choice for HHS secretary, is unfit for that role and should not be confirmed, 77 Nobel laureates said in a letter to members of the U.S. Senate.
